Document Detail


Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature.
MedLine Citation:
PMID:  22926198     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSIONS: 1. Rapid cessation of ERT results not only in the loss of the beneficial effects, but in a significant worsening of the patient's clinical status. 2. Decisions about the introduction of ERT, especially in patients severely affected, should be made carefully. 3. Once started, it is essential to keep an adequate administration schedule of ERT to maintain the clinical benefits of enzyme therapy.
Authors:
Agnieszka Jurecka; Zbigniew Żuberuber; Violetta Opoka-Winiarska; Grzegorz Węgrzyn; Anna Tylki-Szymańska
Related Documents :
18854058 - Tracheopathia chondro-osteoplastica--an unusual cause of stridor.
23569508 - Synovial sarcoma leading to a paraesophageal abscess in a child.
23006548 - Wound healing after radiation therapy: review of the literature.
11722078 - A case of asymptomatic thoracic aorta mural thrombi.
10743748 - Glaucoma and race: a case for screening in connecticut.
22668748 - Malignant pleural mesothelioma in us automotive mechanics: reported vs expected number ...
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2012-08-17
Journal Detail:
Title:  Molecular genetics and metabolism     Volume:  107     ISSN:  1096-7206     ISO Abbreviation:  Mol. Genet. Metab.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-29     Completed Date:  2013-03-27     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9805456     Medline TA:  Mol Genet Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  508-12     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Child
Enzyme Replacement Therapy*
Humans
Iduronate Sulfatase / therapeutic use*
Mucopolysaccharidosis II / drug therapy*,  enzymology,  mortality,  pathology
Survival Analysis
Treatment Outcome
Withholding Treatment / ethics,  utilization*
Young Adult
Chemical
Reg. No./Substance:
EC 3.1.6.13/Iduronate Sulfatase; EC 3.1.6.13/idursulfase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tnf?, Cox2 and AdipoQ adipokine gene expression levels are modulated in murine adipose tissues by bo...
Next Document:  Intrathecal chlorprothixene, cis(z)-flupenthixol, chlorpromazine and fluphenazine for prolonged spin...